Advertisement
Patient-Oriented and Epidemiological Research| Volume 59, ISSUE 5, P872-883, 2018

Download started.

Ok

Apolipoprotein-defined lipoprotein subclasses, serum apolipoproteins, and carotid intima-media thickness in T1D

Open AccessPublished:March 25, 2018DOI:https://doi.org/10.1194/jlr.P080143
Apolipoprotein-defined lipoprotein subclasses, serum apolipoproteins, and carotid intima-media thickness in T1D
Previous ArticleAspirin alone and combined with a statin suppresses eicosanoid formation in human colon tissue[S]
Next ArticleLPA kringle IV type 2 is associated with type 2 diabetes in a Chinese population with very high cardiovascular risk
      Circulating apolipoprotein-defined lipoprotein subclasses (ADLS) and apolipoproteins predict vascular events in the general and type 2 diabetes populations, but data in T1D are limited. We examined associations of ADLS, serum apolipoproteins, and conventional lipids with carotid intima-media thickness (IMT) measured contemporaneously and 6 years later in 417 T1D participants [men: n = 269, age 42 ± 6 y (mean ± SD); women: n = 148, age 39 ± 8 y] in the Epidemiology of Diabetes Interventions and Complications study, the follow-up of the Diabetes Control and Complications Trial (DCCT). Date were analyzed by multiple linear regression stratified by sex, and adjusted for time-averaged hemoglobin A1C, diabetes duration, hypertension, BMI, albuminuria, DCCT randomization, smoking, statin treatment, and ultrasound devices. In cross-sectional analyses, lipoprotein B (Lp-B), Lp-B:C, Lp-B:E+Lp-B:C:E, Apo-A-II, Apo-B, Apo-C-III-HP (heparin precipitate; i.e., Apo-C-III in Apo-B-containing lipoproteins), and Apo-E were positively associated with common and/or internal carotid IMT in men, but only Apo-C-III (total) was (positively) associated with internal carotid IMT in women. In prospective analyses, Lp-B, Apo-B, and Apo-C-III-HP were positively associated with common and/or internal carotid IMT in men, while Lp-A1:AII and Apo-A1 were inversely associated with internal carotid IMT in women. The only significant prospective association between conventional lipids and IMT was between triacylglycerols and internal carotid IMT in men. ADLS and apolipoprotein concentrations may provide sex-specific biomarkers and suggest mechanisms for IMT in people with T1D.
      T1D has been associated with shorter life expectancy and increased risk of atherosclerotic events than in the general population (
      • Livingstone S.J.
      • Levin D.
      • Looker H.C.
      • Lindsay R.S.
      • Wild S.H.
      • Joss N.
      • Leese G.
      • Leslie P.
      • McCrimmon R.J.
      • Metcalfe W.
      • et al.
      Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008–2010.
      JAMA. 2015; 313: 37-44
      ,
      • Lind M.
      • Svensson A.M.
      • Kosiborod M.
      • Gudbjornsdottir S.
      • Pivodic A.
      • Wedel H.
      • Dahlqvist S.
      • Clements M.
      • Rosengren A.
      Glycemic control and excess mortality in type 1 diabetes.
      N. Engl. J. Med. 2014; 371: 1972-1982
      ). Dyslipidemia is an independent vascular risk factor, and both quantitative and qualitative changes in lipoproteins are implicated (
      • Jenkins A.J.
      • Lyons T.J.
      • Zheng D.
      • Otvos J.D.
      • Lackland D.T.
      • McGee D.
      • Garvey W.T.
      • Klein R.L.
      Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy.
      Kidney Int. 2003; 64: 817-828
      ,
      • Lyons T.J.
      • Jenkins A.J.
      • Zheng D.
      • Klein R.L.
      • Otvos J.D.
      • Yu Y.
      • Lackland D.T.
      • McGee D.
      • McHenry M.B.
      • Lopes-Virella M.
      • et al.
      Nuclear magnetic resonance-determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with carotid intima-media thickness.
      Diabet. Med. 2006; 23: 955-966
      ). Lipid-lowering therapies, especially “statins,” substantially reduce the risk of cardiovascular events in people with either T1D or T2D (
      • Kearney P.M.
      • Blackwell L.
      • Collins R.
      • Keech A.
      • Simes J.
      • Peto R.
      • Armitage J.
      • Baigent C.
      Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.
      Lancet. 2008; 371: 117-125
      ). Thus, serum lipids and lipoproteins are important biomarkers for atherosclerosis progression, and detailed lipid and lipoprotein subclasses, such as those based on size and density, are known to extend and complement associations of conventional lipid profiles with the vascular complications of diabetes (
      • Lyons T.J.
      • Jenkins A.J.
      • Zheng D.
      • Klein R.L.
      • Otvos J.D.
      • Yu Y.
      • Lackland D.T.
      • McGee D.
      • McHenry M.B.
      • Lopes-Virella M.
      • et al.
      Nuclear magnetic resonance-determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with carotid intima-media thickness.
      Diabet. Med. 2006; 23: 955-966
      ,
      • Basu A.
      • Jenkins A.J.
      • Zhang Y.
      • Stoner J.A.
      • Klein R.L.
      • Lopes-Virella M.F.
      • Garvey W.T.
      • Lyons T.J.
      Nuclear magnetic resonance-determined lipoprotein subclasses and carotid intima-media thickness in type 1 diabetes.
      Atherosclerosis. 2016; 244: 93-100
      ,
      • Garvey W.T.
      • Kwon S.
      • Zheng D.
      • Shaughnessy S.
      • Wallace P.
      • Hutto A.
      • Pugh K.
      • Jenkins A.J.
      • Klein R.L.
      • Liao Y.
      Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance.
      Diabetes. 2003; 52: 453-462
      ). Apolipoprotein-defined lipoprotein subclass (ADLS) analysis represents an approach relating to particle function and metabolism: it defines particles according to their qualitative apolipoprotein complement, and the subclass names reflect the apolipoproteins present on the particle (
      • Alaupovic P.
      Significance of apolipoproteins for structure, function, and classification of plasma lipoproteins.
      Methods Enzymol. 1996; 263: 32-60
      ). Lipoproteins can be categorized into two “families,” containing either Apo-A-1 or Apo-B. The Apo-A-1 family overlaps with HDL, includes two subclasses [lipoprotein A-I (Lp-A-I) and Lp-A-I:A-II], and usually has antiatherogenic potential (
      • Alaupovic P.
      The concept of apolipoprotein-defined lipoprotein families and its clinical significance.
      Curr. Atheroscler. Rep. 2003; 5: 459-467
      ,
      • Puchois P.
      • Kandoussi A.
      • Fievet P.
      • Fourrier J.L.
      • Bertrand M.
      • Koren E.
      • Fruchart J.C.
      Apolipoprotein A-I containing lipoproteins in coronary artery disease.
      Atherosclerosis. 1987; 68: 35-40
      ). The Apo-B family includes VLDL, IDL, and LDL; includes five subclasses [lipoprotein B (Lp-B), Lp-B:E, Lp-B:C, Lp-B:C:E, and Lp-A-II:B:C:D:E]; and generally has proatherogenic effects (
      • Alaupovic P.
      Significance of apolipoproteins for structure, function, and classification of plasma lipoproteins.
      Methods Enzymol. 1996; 263: 32-60
      ,
      • Alaupovic P.
      The concept of apolipoprotein-defined lipoprotein families and its clinical significance.
      Curr. Atheroscler. Rep. 2003; 5: 459-467
      ). Findings from lipid-lowering trials, such as the Monitored Atherosclerosis Regression Study and the Cholesterol Lowering Atherosclerosis Study, supported the significance of ADLS, especially high levels of Lp-B and Lp-B:C particles, in predicting coronary events, and these associations remained significant when adjusted for conventional lipid profiles (
      • Blankenhorn D.H.
      • Alaupovic P.
      • Wickham E.
      • Chin H.P.
      • Azen S.P.
      Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors.
      Circulation. 1990; 81: 470-476
      ,
      • Alaupovic P.
      • Hodis H.N.
      • Knight-Gibson C.
      • Mack W.J.
      • LaBree L.
      • Cashin-Hemphill L.
      • Corder C.N.
      • Kramsch D.M.
      • Blankenhorn D.H.
      Effects of lovastatin on ApoA- and ApoB-containing lipoproteins. Families in a subpopulation of patients participating in the Monitored Atherosclerosis Regression Study (MARS).
      Arterioscler. Thromb. 1994; 14: 1906-1913
      ). However, associations between ADLS and carotid intima-media thickness (IMT), a clinically useful surrogate marker of atherosclerosis, have not been explored in T1D.
      ADLS analyses may be compared with, and complemented by, simpler clinically available plasma or serum concentrations of apolipoproteins, measures that contain no information about the distribution of apolipoproteins among particle subclasses [for example, circulating ApoB represents the total amount in VLDL, IDL, LDL, and lipoprotein (a)]. In addition to ApoB, high plasma concentrations of Apo-C-III have been associated with CVD risk (
      • Ooi E.M.
      • Barrett P.H.
      • Chan D.C.
      • Watts G.F.
      Apolipoprotein C–III: understanding an emerging cardiovascular risk factor.
      Clin. Sci. (Lond.). 2008; 114: 611-624
      ). Apo-C-III is involved in the transport and catabolism of triacylglycerols (TGs) and can be bound to Apo-A-1-containing lipoproteins which are heparin-soluble (Apo-C-III HS) or to Apo-B-containing lipoproteins, which are precipitated by heparin (Apo-C-III HP). ApoC-III reduces clearance of lipoproteins by inhibiting lipoprotein lipase and by blocking the binding of Apo-E to hepatic receptors (
      • Ginsberg H.N.
      • Le N.A.
      • Goldberg I.J.
      • Gibson J.C.
      • Rubinstein A.
      • Wang-Iverson P.
      • Norum R.
      • Brown W.V.
      Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.
      J. Clin. Invest. 1986; 78: 1287-1295
      ,
      • Zheng C.
      • Khoo C.
      • Furtado J.
      • Sacks F.M.
      Apolipoprotein C–III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype.
      Circulation. 2010; 121: 1722-1734
      ). The ratio of Apo-C-III HS to Apo-C-III HP (“Apo-C-III ratio”) is considered a useful index of the peripheral catabolism of TG-rich lipoproteins, with higher values being considered favorable (
      • Blackett P.R.
      • Blevins K.S.
      • Quintana E.
      • Stoddart M.
      • Wang W.
      • Alaupovic P.
      • Lee E.T.
      ApoC-III bound to apoB-containing lipoproteins increase with insulin resistance in Cherokee Indian youth.
      Metabolism. 2005; 54: 180-187
      ). Apo-E modulates TG metabolism, and enrichment of Apo-B-containing lipoproteins with Apo-E accelerates uptake of the particles via remnant receptors, increasing atherogenicity (
      • Kowal R.C.
      • Herz J.
      • Weisgraber K.H.
      • Mahley R.W.
      • Brown M.S.
      • Goldstein J.L.
      Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein.
      J. Biol. Chem. 1990; 265: 10771-10779
      ).
      The Diabetes Control and Complications Trial (DCCT) aimed to determine effects of intensive vs. “conventional” diabetes therapy on the development and progression of diabetic microvascular complications (
      • The Diabetes Control and Complications Trial Research Group
      • Nathan D.M.
      • Genuth S.
      • Lachin J.
      • Cleary P.
      • Crofford O.
      • Davis M.
      • Rand L.
      • Siebert C.
      The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
      N. Engl. J. Med. 1993; 329: 977-986
      ). The study cohort comprised 1,441 T1D patients who, at enrollment in 1983–1989, were aged 13–39 years and were free of overt CVD. A primary prevention cohort comprised patients with T1D for 1–5 years and no diabetes-related complications. A secondary intervention cohort comprised patients with T1D for 1–15 years, mild to moderate nonproliferative retinopathy, and urinary albumin excretion rate (AER) <200 mg/day. In 1994, the Epidemiology of Diabetes Interventions and Complications study (EDIC), the longitudinal observational follow-up of the DCCT cohort, was initiated to assess the long-term effects of the prior DCCT intervention on cardiovascular and other complications (
      • The Diabetes Control and Complications Trial Research Group
      • Nathan D.M.
      • Genuth S.
      • Lachin J.
      • Cleary P.
      • Crofford O.
      • Davis M.
      • Rand L.
      • Siebert C.
      Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort.
      Diabetes Care. 1999; 22: 99-111
      ); EDIC is ongoing. Carotid IMT measures were obtained at EDIC years 1 (1994–1996), 6 (1998–2000), and 12 (2004–2006); the ADLS and apolipoprotein measures reported in this study were measured on one occasion at EDIC year 6 and related cross-sectionally and prospectively to IMT at years 6 and 12. We hypothesized that Apo-B-containing lipoproteins, and serum Apo-B and Apo-C-III, are positively associated with IMT, whereas Apo-A-containing lipoproteins and serum Apo-A exhibit protective associations with IMT. The present study is the first to examine the relationship of ADLS and apolipoprotein concentrations with common and internal carotid IMT in T1D patients and complements our recent study of associations with albuminuria (
      • Jenkins A.J.
      • Yu J.
      • Alaupovic P.
      • Basu A.
      • Klein R.L.
      • Lopes-Virella M.
      • Baker N.L.
      • Hunt K.J.
      • Lackland D.T.
      • Garvey W.T.
      • et al.
      Apolipoprotein-defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort.
      J. Diabetes Complications. 2013; 27: 447-453
      ).

      METHODS

      In 1996, a collaboration between the Medical University of South Carolina (MUSC) and DCCT/EDIC was initiated to identify vascular risk factors. Twenty-five of 28 DCCT/EDIC clinical centers participated, and in 1997–1999, serum samples were shipped overnight on ice to MUSC; on arrival, aliquots were promptly prepared and stored at −80°C until analysis. The study, which meets Declaration of Helsinki guidelines, was approved by the Institutional Review Boards at MUSC and all participating DCCT/EDIC centers. Each subject gave written informed consent. Of the 1,441 DCCT participants, 968 agreed to participate in the MUSC program, but cost and resource considerations precluded determination of ADLS and apolipoprotein concentrations in all of these. The present study therefore utilized a previously described subset (n = 465) (
      • Kowal R.C.
      • Herz J.
      • Weisgraber K.H.
      • Mahley R.W.
      • Brown M.S.
      • Goldstein J.L.
      Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein.
      J. Biol. Chem. 1990; 265: 10771-10779
      ,
      • The Diabetes Control and Complications Trial Research Group
      • Nathan D.M.
      • Genuth S.
      • Lachin J.
      • Cleary P.
      • Crofford O.
      • Davis M.
      • Rand L.
      • Siebert C.
      Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort.
      Diabetes Care. 1999; 22: 99-111
      ), of whom 417 had IMT measures available. Briefly, all those with abnormal albuminuria (AER > 40 mg/24 h), increased Early Treatment Diabetic Retinopathy Study retinopathy score (≥10), or elevated carotid atherosclerosis (≥25% stenosis at a carotid lesion) were included (i.e., all available cases were sampled), together with a larger group of subjects free of all of these complications. The three disease categories (albuminuria, retinopathy, and carotid stenosis ≥25%) were combined and reweighted to reflect the demographic and vascular disease status of the entire EDIC cohort (see Statistical Analyses below).

      Carotid ultrasonography and image analysis

      Common and internal carotid IMT measurements in EDIC have previously been described in detail (
      • Nathan D.M.
      • Lachin J.
      • Cleary P.
      • Orchard T.
      • Brillon D.J.
      • Backlund J.Y.
      • O'Leary D.H.
      • Genuth S.
      Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus.
      N. Engl. J. Med. 2003; 348: 2294-2303
      ,
      • Polak J.F.
      • Backlund J.Y.
      • Cleary P.A.
      • Harrington A.P.
      • O'Leary D.H.
      • Lachin J.M.
      • Nathan D.M.
      Progression of carotid artery intima-media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Dia­betes Interventions and Complications (DCCT/EDIC) study.
      Diabetes. 2011; 60: 607-613
      ). In this substudy, associations of lipoprotein measures with common and internal carotid IMT were assessed cross-sectionally at EDIC year 6 and prospectively at EDIC year 12. The IMT measures defined the maximum IMT for each individual. Reliability measures for IMT readers at EDIC years 6 and 12 have been reported previously (
      • Polak J.F.
      • Backlund J.Y.
      • Cleary P.A.
      • Harrington A.P.
      • O'Leary D.H.
      • Lachin J.M.
      • Nathan D.M.
      Progression of carotid artery intima-media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Dia­betes Interventions and Complications (DCCT/EDIC) study.
      Diabetes. 2011; 60: 607-613
      ): briefly, for common carotid IMT, intrareader and interreader coefficients of reliability were >0.93 and >0.81 respectively, and for internal carotid IMT, >0.93 and >0.90.

      ADLS measures and serum apolipoproteins

      The concept of ADLS addresses the functional significance of apolipoprotein heterogeneity that is not evident from conventional density-based lipoprotein classification methods (
      • Alaupovic P.
      Significance of apolipoproteins for structure, function, and classification of plasma lipoproteins.
      Methods Enzymol. 1996; 263: 32-60
      ,
      • Alaupovic P.
      The concept of apolipoprotein-defined lipoprotein families and its clinical significance.
      Curr. Atheroscler. Rep. 2003; 5: 459-467
      ). This heterogeneity is an important determinant of metabolism and, thus, atherogenicity. Assays were conducted in the Lipid and Lipoprotein Laboratory at the Oklahoma Medical Research Foundation using previously described procedures (
      • Attman P.O.
      • Alaupovic P.
      • Gustafson A.
      Serum apolipoprotein profile of patients with chronic renal failure.
      Kidney Int. 1987; 32: 368-375
      ,
      • Hilpert K.F.
      • West S.G.
      • Kris-Etherton P.M.
      • Hecker K.D.
      • Simpson N.M.
      • Alaupovic P.
      Postprandial effect of n-3 polyunsaturated fatty acids on apolipoprotein B-containing lipoproteins and vascular reactivity in type 2 diabetes.
      Am. J. Clin. Nutr. 2007; 85: 369-376
      ). Briefly, for Apo-B-containing particles, 100 µl of whole plasma was mixed with buffer solution, then sequentially treated with polyclonal antisera to apo A-II, followed by antisera to Apo-E, and finally with antisera to Apo-C-III, with overnight incubations at each step followed by centrifugation to separate the precipitates and supernatants (
      • Hilpert K.F.
      • West S.G.
      • Kris-Etherton P.M.
      • Hecker K.D.
      • Simpson N.M.
      • Alaupovic P.
      Postprandial effect of n-3 polyunsaturated fatty acids on apolipoprotein B-containing lipoproteins and vascular reactivity in type 2 diabetes.
      Am. J. Clin. Nutr. 2007; 85: 369-376
      ). Lp-B, Lp-B:C, (Lp-B:E + Lp-B:C:E), and Lp-A-II:B:C:D:E particle levels were expressed according to Apo-B content (
      • Hilpert K.F.
      • West S.G.
      • Kris-Etherton P.M.
      • Hecker K.D.
      • Simpson N.M.
      • Alaupovic P.
      Postprandial effect of n-3 polyunsaturated fatty acids on apolipoprotein B-containing lipoproteins and vascular reactivity in type 2 diabetes.
      Am. J. Clin. Nutr. 2007; 85: 369-376
      ). Lp-A-I and Lp-A-I:A-II were measured by differential turbidimetry and defined according to Apo-A-I content (
      • März W.
      • Trommlitz M.
      • Gross W.
      Differential turbidimetric assay for subpopulations of lipoproteins containing apolipoprotein A-I.
      J. Clin. Chem. Clin. Biochem. 1988; 26: 573-578
      ). Quantification of Apo-C-III bound to Apo-A- and to Apo-B-containing lipoproteins was performed on heparin–manganese supernatants (Apo-C-III-HS) and precipitates (Apo-C-III-HP), respectively (
      • Ginsberg H.N.
      • Le N.A.
      • Goldberg I.J.
      • Gibson J.C.
      • Rubinstein A.
      • Wang-Iverson P.
      • Norum R.
      • Brown W.V.
      Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.
      J. Clin. Invest. 1986; 78: 1287-1295
      ). Apolipoproteins were quantified by electroimmunoassays for Apo-A-I, Apo-A-II, Apo-B, Apo-C-III, and Apo-E (
      • Alaupovic P.
      The concept of apolipoprotein-defined lipoprotein families and its clinical significance.
      Curr. Atheroscler. Rep. 2003; 5: 459-467
      ).

      Conventional lipid profiles, hemoglobin A1C, and other clinical measurements

      These assays were performed at the DCCT/EDIC Central Biochemistry Laboratory (University of Minnesota). Total cholesterol, triglyceride, and HDL-cholesterol levels were determined by using previously reported enzymatic methods (
      • Jenkins A.J.
      • Lyons T.J.
      • Zheng D.
      • Otvos J.D.
      • Lackland D.T.
      • McGee D.
      • Garvey W.T.
      • Klein R.L.
      Serum lipoproteins in the diabetes control and complications trial/epidemiology of diabetes intervention and complications cohort: associations with gender and glycemia.
      Diabetes Care. 2003; 26: 810-818
      ). LDL-cholesterol was estimated according to the Friedewald equation. Hemoglobin A1C (HbA1C) was measured by high-performance ion exchange liquid chromatography (
      • The DCCT Research Group
      Feasibility of centralized measurements of glycated hemoglobin in the Diabetes Control and Complications Trial: a multicenter study.
      Clin. Chem. 1987; 33: 2267-2271
      ).

      Statistical analyses

      In order to generate statistical estimates representative of the entire EDIC cohort, the distributions of cross-tabulated retinopathy, nephropathy, and carotid stenosis disease categories were determined for both the sampled subset and for the entire EDIC cohort. Inverse probability of selection weights was then calculated for each combination of disease status measures, by dividing the relative frequency among the entire EDIC cohort by the relative frequency among the sampled subset. The resulting weights were used in all statistical analyses (
      • Nathan D.M.
      • McGee P.
      • Steffes M.W.
      • Lachin J.M.
      Relationship of glycated albumin to blood glucose and HbA1c values and to retinopathy, nephropathy, and cardiovascular outcomes in the DCCT/EDIC study.
      Diabetes. 2014; 63: 282-290
      ,
      • Lopes-Virella M.F.
      • Baker N.L.
      • Hunt K.J.
      • Lyons T.J.
      • Jenkins A.J.
      • Virella G.
      High concentrations of AGE-LDL and oxidized LDL in circulating immune complexes are associated with progression of retinopathy in type 1 diabetes.
      Diabetes Care. 2012; 35: 1333-1340
      ).
      Common and internal carotid IMT, ADLS, most apolipoprotein concentrations, conventional lipids, and clinical and demographic factors measured at EDIC year 6, if normally distributed, were analyzed as continuous variables, presented as means ± SD, and compared according to sex using Student t-tests. Variables with skewed distributions [diabetes duration, urinary AER, triglycerides, and Apo-C-III (total and HP)], were summarized as medians and interquartile ranges; the sexes were compared by using the Wilcoxon rank sum test. Data expressed as proportions, e.g., smoking (current), prior statin use at EDIC year 6, and original DCCT randomization group and status (primary or secondary at DCCT baseline), were compared between the sexes using a χ2 test.
      Multiple linear regression analyses were performed to examine associations of the EDIC year 6 lipoprotein-related measures (ADLS, apolipoprotein concentrations, and conventional lipid profiles) with the two dependent variables: common and internal carotid IMT. These associations were assessed in cross-sectional analyses using IMT data from EDIC year 6 and prospective analyses using IMT data from EDIC year 12, again stratified by sex. Results of unadjusted (univariate) analyses and adjusted (multivariate) analyses are presented in the tables. For the adjusted analyses, each lipoprotein measure was included as an independent variable in the linear model simultaneously with a fixed group of covariates (also from EDIC year 6): diabetes duration, smoking (yes/no), DCCT treatment group, hypertension (systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, or treatment with antihypertensive medications), BMI, AER, HbA1C, and ultrasound imaging device. Prior statin use, defined at EDIC year 6 and, for prospective analyses, also at EDIC year 12, was also included in the adjusted models. A similar modeling approach was used for the analysis of IMT changes over 6 years (EDIC year 12 minus year 6 IMT) and their associations with EDIC year 6 lipoprotein-related measures. Variables with skewed distributions were log-transformed (natural log) to satisfy linear modeling assumptions.
      Two other analyses are presented as text in the Results. First, a “final combined model” was fit that included all ADLS, serum apolipoprotein concentrations, and conventional lipid measures that were significant at the 0.05 α level: this was to identify measures that were independently associated with IMT: two-tailed P values < 0.05 were considered statistically significant. Second, to take multiple comparisons into account, the P value for significance was taken as ≤0.001 based on a Bonferroni adjustment. Data were analyzed by using SAS/STAT software (Version 9.4; SAS Institute Inc., Cary, NC).

      RESULTS

      Subject characteristics

      Oversampling of participants with evidence of vascular complications resulted in more men than women in the study subset. As shown in Table 1, at EDIC year 6 “baseline” in men compared with women, age, BMI, systolic blood pressure, estimated glomerular filtration rate, triglycerides, LDL- and nonHDL-cholesterol were significantly higher, and HDL-cholesterol was significantly lower. Among the ADLS-related measures, men had significantly higher Lp-B and Lp-B:C and significantly lower Lp-A-I and Lp-A-I:A-II than women. Among apolipoprotein concentrations, men had higher Apo-C-III HP, lower Apo-C-III ratios, and lower Apo-A-1 than women (all P < 0.05). In view of all these differences, for the presentation of data below, men and women were analyzed separately.
      TABLE 1EDIC year 6 characteristics (1997–2000) of the reported subset of EDIC participants (n = 417), according to sex
      CharacteristicsMen (n = 269) (mean ± SD)
      If the distribution of a continuous variable is skewed, median and the interquartile range (Q1, Q3) are presented.
      		Women (n = 148) (mean ± SD)
      If the distribution of a continuous variable is skewed, median and the interquartile range (Q1, Q3) are presented.
      		P
      If the distribution of a continuous variable is skewed, median and the interquartile range (Q1, Q3) are presented.
      Age (years)41.5 ± 5.939.0 ± 8.30.0015
      Intensive treatment (%)48440.42
      Secondary Intervention (%)53500.65
      Duration of diabetes (years)
      If the distribution of a continuous variable is skewed, median and the interquartile range (Q1, Q3) are presented.
      		17 (15, 22)18 (16, 23)0.051
      Current cigarette smoker (%)16140.59
      Any prior statin use (%)630.14
      Hypertension (%)41260.0019
      BMI (kg/m2)27.4 ± 3.526.1 ± 4.80.0026
      Blood pressure (mmHg)
      Systolic123 ± 11119 ± 180.0049
      Diastolic77 ± 775 ± 110.054
      AER (mg/24 h)
      If the distribution of a continuous variable is skewed, median and the interquartile range (Q1, Q3) are presented.
      		11.5 (8.6, 31.7)11.5 (5.7, 17.3)0.14
      Glomerular filtration rate (ml/min)92.6 ± 18.587.8 ± 18.60.010
      HbA1c (%) [weighted mean]8.2 ± 1.08.2 ± 1.50.71
      ADLS measures
      Lp-B (mg ApoB/dl)37.2 ± 9.535.2 ± 11.40.049
      Lp-B:C (mg ApoB/dl)12.1 ± 3.511.2 ± 4.50.033
      Lp-B:E + Lp-B:C:E (mg ApoB/dl)11.7 ± 4.012.4 ± 4.60.13
      Lp-A-II:B:C:D:E (mg ApoB/dl)13.1 ± 3.813.2 ± 5.80.90
      Lp-A-I (mg ApoA-1/dl)39.2 ± 6.740.8 ± 9.10.043
      Lp-A-I:A-II (mg ApoA-I/dl)101.9 ± 21.2111.7 ± 26.1<0.0001
      Serum apolipoproteins
      Apo-B (mg/dl)74.1 ± 15.571.9 ± 20.70.24
      Apo-A-I (mg/dl)141.1 ± 26.6152.6 ± 33.70.0002
      Apo-A-II (mg/dl)35.4 ± 11.136.5 ± 12.40.40
      Apo-C-III total (mg/dl)
      If the distribution of a continuous variable is skewed, median and the interquartile range (Q1, Q3) are presented.
      		9.4 (7.4, 11.0)9.2 (7.8, 11.1)0.94
      Apo-C-III HP (mg/dl)
      Comparison between men and women: t-test for difference in means, Wilcoxon rank sum test for difference in medians, and χ2 test for difference in proportions. P values are shown in bold if significant (<0.05).
      		2.4 (1.9, 3.2)2.1 (1.6, 2.9)0.019
      Apo-C-III HS (mg/dl)6.8 ± 2.07.2 ± 2.20.12
      Apo-C-III ratio
      Apo-C-III ratio is the ratio of Apo-C-III-HS:Apo-C-III-HP (an index of peripheral catabolism of TG-rich lipoproteins)
      		2.7 ± 0.73.2 ± 1.1<0.0001
      Apo-E (mg/dl)4.3 ± 1.04.1 ± 1.00.095
      Conventional lipids
      Total cholesterol (mg/dl)190.3 ± 30.8187.9 ± 37.80.49
      Triglyceride (mg/dl)
      If the distribution of a continuous variable is skewed, median and the interquartile range (Q1, Q3) are presented.
      		79 (57, 118)66 (48, 87)<0.0001
      LDL-cholesterol (mg/dl)117.5 ± 24.7111.4 ± 34.60.044
      Non-HDL-cholesterol (mg/dl)138.8 ± 31.3126.3 ± 39.10.0005
      HDL-cholesterol (mg/dl)51.5 ± 11.161.5 ± 16.0<0.0001
      Carotid IMT
      Common carotid IMT (mm)0.677 ± 0.1180.607 ± 0.099<0.0001
      Internal carotid IMT (mm)0.836 ± 0.3560.693 ± 0.298<0.0001
      a If the distribution of a continuous variable is skewed, median and the interquartile range (Q1, Q3) are presented.
      b Comparison between men and women: t-test for difference in means, Wilcoxon rank sum test for difference in medians, and χ2 test for difference in proportions. P values are shown in bold if significant (<0.05).
      c Apo-C-III ratio is the ratio of Apo-C-III-HS:Apo-C-III-HP (an index of peripheral catabolism of TG-rich lipoproteins)

      ADLS measures, serum apolipoproteins and carotid IMT: cross-sectional associations (EDIC year 6)

      Cross-sectional associations of lipids/lipoproteins (ADLS, serum apolipoprotein concentrations, and conventional lipids) with common and internal carotid IMT at EDIC year 6 are shown in Tables 2 and 3, respectively. In men, by unadjusted analysis, Lp-B, Lp-B:C, Apo-B, and Apo-C-III HP were positively associated with common carotid IMT, while Apo-C-III ratio was inversely associated (Table 2). In adjusted analysis, the positive associations of Lp-B:C and Apo-B persisted, and, in addition, Lp-B:E + Lp-B:C:E, Apo-AII, and Apo-E became statistically significant. Also in men, by unadjusted analysis, all conventional lipid profile measures, except triglyceride and HDL-cholesterol, were associated with common carotid IMT, but only total cholesterol remained in adjusted analysis. In the final combined model, Apo-E (slope = 0.038, SE = 0.013, P = 0.005) and Apo-B (slope = 0.0027, SE = 0.0009, P = 0.0028) remained significant among the lipid/lipoprotein measures. For women, there was a significant inverse association between Apo-C-III ratio and common carotid IMT (unadjusted analysis), but no other significant associations were observed.
      TABLE 2EDIC Year 6 ADLS and serum apolipoprotein measures vs. common carotid IMT
      Models were adjusted for DCCT randomization, AER, HbA1C, diabetes duration, hypertension, BMI, and current smoking at EDIC year 6. The regression models were also adjusted for statin use (any time from DCCT baseline to EDIC year 6), ultrasound devices, and image readers at EDIC year 6.
      at EDIC year 6 (linear regression coefficients)
      Men (n = 269)Women (n = 148)
      UnadjustedAdjusted
      Models were adjusted for DCCT randomization, AER, HbA1C, diabetes duration, hypertension, BMI, and current smoking at EDIC year 6. The regression models were also adjusted for statin use (any time from DCCT baseline to EDIC year 6), ultrasound devices, and image readers at EDIC year 6.
      		UnadjustedAdjusted
      Models were adjusted for DCCT randomization, AER, HbA1C, diabetes duration, hypertension, BMI, and current smoking at EDIC year 6. The regression models were also adjusted for statin use (any time from DCCT baseline to EDIC year 6), ultrasound devices, and image readers at EDIC year 6.
      VariablesSlopeSEPSlopeSEPSlopeSEPSlopeSEP
      ADLS measures
      Lp-B (mg ApoB/d0.00300.00100.0040.00160.00120.17−0.000010.00120.99−0.00010.00130.95
      Lp-B:C (mg ApoB/dl)0.00860.00280.0020.00800.00290.0056−0.00170.00310.59−0.00300.00320.36
      Lp-B:E + Lp-B:C:E (mg ApoB/dl)0.00440.00260.0890.00640.00270.018−0.00150.00300.62−0.00040.00300.89
      Lp-A-II:B:C:D:E (mg ApoB/dl)0.00480.00250.0630.00320.00270.24−0.00140.00240.57−0.00100.00290.74
      Lp-A-I (mg ApoA-I/dl)0.00130.00150.390.00130.00160.41−0.00230.00150.12−0.00110.00150.47
      Lp-A-I:A-II (mg ApoA-I/dl)−0.00040.00050.440.000010.00050.99−0.00100.00050.061−0.00040.00050.44
      Serum apolipoproteins
      Apo-B (mg/dl)0.00220.0006<0.0010.00170.00070.014−0.00020.000070.73−0.00030.00080.74
      Apo-A-I (mg/dl)−0.00020.00040.550.000040.00040.92−0.00080.00040.062−0.00030.00040.43
      Apo-A-II (mg/dl)0.00080.00120.530.00310.00130.019−0.00130.00110.22−0.000030.00110.98
      Apo-C-III total (mg/dl)
      Triglyceride, Apo-C-III total, and Apo-C-III HP and common carotid IMT measures were natural log-transformed.
      		0.0470.0330.150.0310.0340.37−0.0150.0420.720.00500.0450.91
      Apo-C-III HP (mg/dl)
      Triglyceride, Apo-C-III total, and Apo-C-III HP and common carotid IMT measures were natural log-transformed.
      		0.0620.0260.0200.0360.0290.230.0510.0300.0980.0320.0310.31
      Apo-C-III HS (mg/dl)0.00620.00490.210.00570.00520.28−0.00410.00610.500.00020.00630.98
      Apo-C-III ratio
      Apo-C-III ratio: the ratio of Apo-C-III-HS:Apo-C-III-HP (an index of peripheral catabolism of TG-rich lipoproteins).
      		-0.0260.0130.045−0.00650.0140.63-0.0340.0120.005−0.0170.0120.17
      Apo-E (mg/dl)0.0160.0130.230.0370.0140.00750.00880.0130.510.0190.0140.18
      Conventional lipids
      Total cholesterol (mg/dl)0.00090.00030.0030.00070.00030.0360.000050.00040.89−0.00010.00040.87
      Triglyceride (mg/dl)
      Triglyceride, Apo-C-III total, and Apo-C-III HP and common carotid IMT measures were natural log-transformed.
      		0.0330.0200.0900.0140.0200.490.00880.0270.750.00300.0280.92
      LDL cholesterol (mg/dl)0.00090.00040.0230.00050.00040.190.00030.00040.460.00010.00050.77
      Non-HDL cholesterol (mg/dl)0.00090.00030.0040.00060.00030.0580.00030.00040.490.00010.00040.87
      HDL cholesterol (mg/dl)0.000030.00090.970.00030.00090.71−0.00110.00090.21−0.00060.00090.48
      values are in bold if significant (<0.05).
      a Models were adjusted for DCCT randomization, AER, HbA1C, diabetes duration, hypertension, BMI, and current smoking at EDIC year 6. The regression models were also adjusted for statin use (any time from DCCT baseline to EDIC year 6), ultrasound devices, and image readers at EDIC year 6.
      b Triglyceride, Apo-C-III total, and Apo-C-III HP and common carotid IMT measures were natural log-transformed.
      c Apo-C-III ratio: the ratio of Apo-C-III-HS:Apo-C-III-HP (an index of peripheral catabolism of TG-rich lipoproteins).
      TABLE 3EDIC year 6 ADLS and serum apolipoprotein measures vs. internal carotid IMT
      Triglyceride, Apo-C-III total, and Apo-C-III HP and common carotid IMT measures were natural log-transformed.
      at EDIC year 6 (linear regression coefficients)
      Men (n = 269)Women (n = 148)
      UnadjustedAdjusted
      Models were adjusted for DCCT randomization, AER, HbA1C, diabetes duration, hypertension, BMI, and current smoking at EDIC year 6. The regression models were also adjusted for statin use (any time from DCCT baseline to EDIC year 6), ultrasound devices, and image readers at EDIC year 6.
      		UnadjustedAdjusted
      Models were adjusted for DCCT randomization, AER, HbA1C, diabetes duration, hypertension, BMI, and current smoking at EDIC year 6. The regression models were also adjusted for statin use (any time from DCCT baseline to EDIC year 6), ultrasound devices, and image readers at EDIC year 6.
      VariablesSlopeSEPSlopeSEPSlopeSEPSlopeSEP
      ADLS measures
      Lp-B (mg ApoB/dl)0.00570.00220.0100.00500.00250.0500.00140.00240.570.00060.00280.84
      Lp-B:C (mg ApoB/dl)0.0150.00590.0150.0170.00630.00700.00020.00620.97−0.00160.00710.82
      Lp-B:E + Lp-B:C:E (mg ApoB/dl)0.01390.00540.0110.0150.00580.00950.00010.00600.990.00430.00650.51
      Lp-A-II:B:C:D:E (mg ApoB/dl)0.00370.00550.50−0.00380.00590.530.00830.00480.0890.00610.00620.33
      Lp-A-I (mg ApoA-I/dl)−0.00020.00310.96−0.00190.00340.59−0.00110.00310.730.00060.00330.85
      Lp-A-I:A-II (mg ApoA-I/dl)−0.00040.00100.72−0.00010.00110.94−0.00110.00110.30−0.00040.00110.74
      Serum apolipoproteins
      Apo-B (mg/dl)0.00410.00140.0030.00350.00150.0190.00120.00130.390.00100.00160.55
      Apo-A-I (mg/dl)−0.00040.00080.62−0.00030.00090.76−0.00070.00080.37−0.00020.00090.83
      Apo-A-II (mg/dl)−0.00040.00270.890.00220.00290.44−0.00400.00220.07−0.00210.00230.36
      Apo-C-III total (mg/dl)
      Triglyceride, Apo-C-III total, and Apo-C-III HP and common carotid IMT measures were natural log-transformed.
      		0.160.0700.0190.150.0750.0510.140.0830.0860.210.0940.025
      Apo-C-III HP (mg/dl)
      Triglyceride, Apo-C-III total, and Apo-C-III HP and common carotid IMT measures were natural log-transformed.
      		0.170.0560.0020.170.0630.00940.120.0610.0470.120.0660.077
      Apo-C-III HS (mg/dl)0.0190.0110.0710.0150.0110.200.0140.0120.270.0220.0140.10
      Apo-C-III ratio
      Apo-C-III ratio is the ratio of Apo-C-III-HS:Apo-C-III-HP (an index of peripheral catabolism of TG-rich lipoproteins).
      		-0.0560.0270.039−0.0430.0290.14−0.0270.0250.27−0.00940.0270.73
      Apo-E (mg/dl)0.00120.0290.680.0240.0300.420.0240.0280.390.0340.0310.27
      Conventional lipids
      Total cholesterol (mg/dl)0.00150.00070.0240.00120.00070.0920.00150.00080.0620.00180.00090.048
      Triglyceride (mg/dl)
      Triglyceride, Apo-C-III total, and Apo-C-III HP and common carotid IMT measures were natural log-transformed.
      		0.0940.0410.0240.0800.0440.0680.0340.0560.540.0550.0620.38
      LDL cholesterol (mg/dl)0.00180.00080.0280.00170.00090.0660.00170.00090.0610.00160.00100.13
      Non-HDL cholesterol (mg/dl)0.00180.00070.0050.00170.00070.0170.00150.00080.0570.00150.00090.11
      HDL cholesterol (mg/dl)−0.00330.00190.086-0.00420.00200.036−0.000040.00180.980.00150.00200.45
      values are in bold if significant (<0.05).
      a Models were adjusted for DCCT randomization, AER, HbA1C, diabetes duration, hypertension, BMI, and current smoking at EDIC year 6. The regression models were also adjusted for statin use (any time from DCCT baseline to EDIC year 6), ultrasound devices, and image readers at EDIC year 6.
      b Triglyceride, Apo-C-III total, and Apo-C-III HP and common carotid IMT measures were natural log-transformed.
      c Apo-C-III ratio is the ratio of Apo-C-III-HS:Apo-C-III-HP (an index of peripheral catabolism of TG-rich lipoproteins).
      Broadly similar cross-sectional associations were seen for internal carotid IMT (Table 3). In men, by unadjusted analyses, Lp-B, Lp-B:C, (Lp-B:E + Lp-B:C:E), Apo-B, Apo-C-III total, and Apo-C-III HP were positively associated with internal carotid IMT, while Apo-C-III ratio was inversely associated. All of the significant associations, except those for total Apo-C-III (P = 0.051) and Apo-C-III ratio (P = 0.14), persisted in adjusted analyses. Also in men, by unadjusted analysis, all conventional lipid measures except HDL-cholesterol were significantly associated with internal carotid IMT, and nonHDL cholesterol and (inversely) HDL-cholesterol were associated in adjusted analysis. In the final combined model, only Lp-B:C remained significant in men. In women, by unadjusted analysis, there was a significant association between Apo-C-III HP and internal carotid IMT, and in adjusted analyses, for total Apo-C-III; only total cholesterol was significant among conventional lipid profile measures. In the final combined model, Apo-C-III HP was no longer significantly associated with internal carotid IMT in women.

      ADLS measures, serum apolipoproteins, and carotid IMT: prospective associations (EDIC year 12)

      Prospective associations of ADLS, plasma apolipoprotein concentrations, and conventional lipid profiles with common and internal carotid IMT are shown in Tables 4 and 5, respectively. In men, by unadjusted analysis, baseline Lp-B, Lp-B:C, Lp-AII:B:C:D:E, Apo-B, and nonHDL cholesterol were significantly positively associated with year 12 common carotid IMT, while the Apo-CIII HP (P = 0.065) and Apo-CIII ratio (inverse, P = 0.054) exhibited trends (Table 4). By adjusted analyses, Apo-B and Lp-B remained significant, but neither remained in the final combined model. For women, there were no statistically significant prospective associations between any lipid/lipoprotein measure and subsequent common carotid IMT with or without adjustment (Table 4).
      TABLE 4EDIC year 6 ADLS and serum apolipoprotein measures vs. common carotid IMT
      Triglyceride, Apo-C-III total, and Apo-C-III HP and common carotid IMT measures were natural log-transformed.
      at EDIC year 12 (linear regression coefficients)
      Men (n = 269)Women (n = 148)
      UnadjustedAdjusted
      Models were adjusted for DCCT randomization, AER, HbA1C, diabetes duration, hypertension, BMI, and current smoking at EDIC year 6. The regression models were also adjusted for statin use (any time from DCCT baseline to EDIC year 12), ultrasound devices, and image readers at EDIC year 12.
      		UnadjustedAdjusted
      Models were adjusted for DCCT randomization, AER, HbA1C, diabetes duration, hypertension, BMI, and current smoking at EDIC year 6. The regression models were also adjusted for statin use (any time from DCCT baseline to EDIC year 12), ultrasound devices, and image readers at EDIC year 12.
      VariablesSlopeSEPSlopeSEPSlopeSEPSlopeSEP
      ADLS measures
      Lp-B (mg ApoB/dl)0.00350.00120.00460.00290.00150.044−0.00110.00110.32−0.00250.00160.11
      Lp-B:C (mg ApoB/dl)0.00760.00340.0250.00720.00380.061−0.00310.00290.29−0.00270.00360.46
      Lp-B:E + Lp-B:C:E (mg ApoB/dl)0.00490.00310.120.00500.00350.15−0.00090.00280.75−0.00030.00370.92
      Lp-A-II:B:C:D:E (mg ApoB/dl)0.00760.00310.0140.00540.00340.11−0.00210.00230.35−0.00220.00310.49
      Lp-A-I (mg ApoA-I/dl)0.00060.00180.730.00110.00200.60−0.000080.00140.960.00140.00150.38
      Lp-A-I:A-II (mg ApoA-I/dl)−0.00080.00060.170.00020.00060.79−0.00060.00050.25−0.000030.00060.95
      Serum apolipoproteins
      Apo-B (mg/dl)0.00260.00080.0010.00220.00090.014−0.00070.00060.28−0.00130.00100.17
      Apo-A-I (mg/dl)−0.00050.00040.220.00010.00050.86−0.00030.00040.370.00010.00040.85
      Apo-A-II (mg/dl)−0.00090.00150.540.00050.00160.77−0.00070.00100.50−0.00010.00110.96
      Apo-C-III total (mg/dl)
      Triglyceride, Apo-C-III total, and Apo-C-III HP and common carotid IMT measures were natural log-transformed.
      		0.0260.0400.52−0.00270.0420.950.0110.0410.78−0.0460.0470.34
      Apo-C-III HP (mg/dl)
      Triglyceride, Apo-C-III total, and Apo-C-III HP and common carotid IMT measures were natural log-transformed.
      		0.0570.0310.0650.0180.0350.600.0180.0290.54−0.0510.0350.14
      Apo-C-III HS (mg/dl)0.00640.00570.260.00490.00610.430.00150.00580.79−0.00280.00660.68
      Apo-C-III ratio
      Apo-C-III ratio is the ratio of Apo-C-III-HS:Apo-C-III-HP (an index of peripheral catabolism of TG-rich lipoproteins).
      		−0.0280.0150.054−0.00700.0170.68−0.00430.0120.710.0160.0130.22
      Apo-E (mg/dl)0.00220.0160.890.0160.0230.480.0100.0130.41−0.00200.0160.90
      Conventional lipids
      Total cholesterol (mg/dl)0.00070.00040.0750.00050.00040.300.00020.00040.510.00010.00040.81
      Triglyceride (mg/dl)
      Triglyceride, Apo-C-III total, and Apo-C-III HP and common carotid IMT measures were natural log-transformed.
      		0.0210.0240.37−0.00690.0250.78−0.00010.0260.99−0.00840.0320.79
      LDL cholesterol (mg/dl)0.00080.00050.0860.00070.00060.250.00050.00040.250.00050.00050.35
      Non-HDL cholesterol (mg/dl)0.00070.00040.0490.00040.00040.430.00040.00040.330.00030.00050.58
      HDL cholesterol (mg/dl)−0.00060.00110.550.00070.00120.54−0.00060.00080.50−0.00060.00090.53
      values are in bold if significant (<0.05).
      a Models were adjusted for DCCT randomization, AER, HbA1C, diabetes duration, hypertension, BMI, and current smoking at EDIC year 6. The regression models were also adjusted for statin use (any time from DCCT baseline to EDIC year 12), ultrasound devices, and image readers at EDIC year 12.
      b Triglyceride, Apo-C-III total, and Apo-C-III HP and common carotid IMT measures were natural log-transformed.
      c Apo-C-III ratio is the ratio of Apo-C-III-HS:Apo-C-III-HP (an index of peripheral catabolism of TG-rich lipoproteins).
      TABLE 5EDIC Year 6 ADLS and serum apolipoprotein measures vs. internal carotid IMT
      Triglyceride, Apo-C-III total, and Apo-C-III HP and common carotid IMT measures were natural log-transformed.
      at EDIC year 12 (linear regression coefficients)
      Men (n = 269)Women (n = 148)
      UnadjustedAdjusted
      Models were adjusted for DCCT randomization, AER, HbA1C, diabetes duration, hypertension, BMI, and current smoking at EDIC year 6. The regression models were also adjusted for statin use (any time from DCCT baseline to EDIC year 12), ultrasound devices, and image readers at EDIC year 12.
      		UnadjustedAdjusted
      Models were adjusted for DCCT randomization, AER, HbA1C, diabetes duration, hypertension, BMI, and current smoking at EDIC year 6. The regression models were also adjusted for statin use (any time from DCCT baseline to EDIC year 12), ultrasound devices, and image readers at EDIC year 12.
      VariablesSlopeSEPSlopeSEPSlopeSEPSlopeSEP
      ADLS measures
      Lp-B (mg ApoB/dl)0.00390.00260.13−0.00180.00290.55−0.00300.00360.40−0.00180.00500.72
      Lp-B:C (mg ApoB/dl)0.0130.00690.0710.00430.00770.58−0.00310.00920.74−0.00490.0120.67
      Lp-B:E + Lp-B:C:E (mg ApoB/dl)0.01460.00630.0220.00670.00700.34−0.00290.00900.75−0.00510.0120.66
      Lp-A-II:B:C:D:E (mg ApoB/dl)0.0160.00630.0140.00830.00680.220.00320.00730.66−0.00380.00980.70
      Lp-A-I (mg ApoA-1/dl)0.00040.00360.90−0.00260.00410.52−0.00230.00460.61−0.00650.00480.18
      Lp-A-I:A-II (mg ApoA-I/dl)−0.00030.00120.810.00010.00130.97−0.00160.00160.32-0.00370.00170.031
      Serum apolipoproteins
      Apo-B (mg/dl)0.00390.00160.0140.00040.00180.83−0.00080.00200.68−0.00150.00300.63
      Apo-A-I (mg/dl)−0.00040.00090.70−0.00030.00100.76−0.00110.00120.36-0.00260.00130.045
      Apo-A-II (mg/dl)−0.00030.00300.920.00210.00320.52−0.00150.00330.65−0.00600.00330.075
      Apo-C-III total (mg/dl)
      Triglyceride, Apo-C-III total, and Apo-C-III HP and common carotid IMT measures were natural log-transformed.
      		0.200.0810.0150.160.0850.0610.190.120.130.0250.140.86
      Apo-C-III HP (mg/dl)
      Triglyceride, Apo-C-III total, and Apo-C-III HP and common carotid IMT measures were natural log-transformed.
      		0.200.0660.0020.180.0720.0150.190.0910.0380.0390.110.72
      Apo-C-III HS (mg/dl)0.0280.0120.0240.0230.0130.0740.0150.0180.41−0.00120.0200.95
      Apo-C-III ratio
      Apo-C-III ratiois the ratio of Apo-C-III-HS:Apo-C-III-HP (an index of peripheral catabolism of TG-rich lipoproteins).
      		−0.0600.0320.063−0.0470.0360.19−0.0440.0370.23−0.0100.0400.80
      Apo-E (mg/dl)0.0410.0320.200.0700.0430.110.0410.0410.31−0.0280.0490.57
      Conventional lipids
      Total cholesterol (mg/dl)0.00160.00080.0470.00040.00090.640.00180.00120.110.00080.00140.56
      Triglyceride (mg/dl)
      Triglyceride, Apo-C-III total, and Apo-C-III HP and common carotid IMT measures were natural log-transformed.
      		0.120.0480.0130.100.0490.0390.0340.0810.680.00940.0990.92
      LDL cholesterol (mg/dl)0.00170.00100.0800.00000.00120.970.00200.00130.130.00110.00170.52
      Non-HDL cholesterol (mg/dl)0.00190.00080.0160.00070.00090.420.00190.00120.100.00110.00150.47
      HDL cholesterol (mg/dl)−0.00270.00220.21−0.00220.00240.36−0.00020.00260.93−0.00070.00290.81
      values are in bold if significant (<0.05).
      a Models were adjusted for DCCT randomization, AER, HbA1C, diabetes duration, hypertension, BMI, and current smoking at EDIC year 6. The regression models were also adjusted for statin use (any time from DCCT baseline to EDIC year 12), ultrasound devices, and image readers at EDIC year 12.
      b Triglyceride, Apo-C-III total, and Apo-C-III HP and common carotid IMT measures were natural log-transformed.
      c Apo-C-III ratiois the ratio of Apo-C-III-HS:Apo-C-III-HP (an index of peripheral catabolism of TG-rich lipoproteins).
      Prospective associations with internal carotid IMT are shown in Table 5. In men, in unadjusted analyses, (Lp-B:E + Lp-B:C:E), Lp-A-II:B:C:D:E, Apo-B, total Apo-C-III, Apo-C-III HP, and Apo-C-III HS were significantly and positively associated with internal carotid IMT 6 years later, with a trend toward a negative association for the Apo-C-III ratio. By adjusted analysis, Apo-C-III-HP and triglyceride levels were significantly associated, but did not persist in the final adjusted model. Also in men, by unadjusted analysis, total cholesterol and nonHDL cholesterol were prospectively associated with internal carotid IMT, but the significance did not persist in adjusted analysis or in the final adjusted model. In women, there was a positive association of Apo-C-III-HP with future internal carotid IMT by unadjusted analysis and negative associations for Lp-A-I:A-II and Apo-A-I in adjusted analyses, but significance did not persist in the final adjusted model. There were no statistically significant associations with conventional lipoprotein measures.
      In the final, most rigorous analysis, accounting for multiple comparisons (and adjusting α-level to 0.001), associations of serum Apo-B with common carotid IMT in men retained significance, observed in unadjusted models and in both cross-sectional and prospective analyses (TABLE 2, TABLE 4).
      We also sought associations of the lipoprotein measures with the change in IMT between EDIC years 6 and 12: only a few scattered associations of borderline significance were seen, regardless of statistical approach (data not shown).

      DISCUSSION

      The DCCT/EDIC is the world's largest and best-characterized longitudinal study to address the evolution of the vascular complications of T1D (
      • The Diabetes Control and Complications Trial Research Group
      • Nathan D.M.
      • Genuth S.
      • Lachin J.
      • Cleary P.
      • Crofford O.
      • Davis M.
      • Rand L.
      • Siebert C.
      The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
      N. Engl. J. Med. 1993; 329: 977-986
      ,
      • The Diabetes Control and Complications Trial Research Group
      • Nathan D.M.
      • Genuth S.
      • Lachin J.
      • Cleary P.
      • Crofford O.
      • Davis M.
      • Rand L.
      • Siebert C.
      Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort.
      Diabetes Care. 1999; 22: 99-111
      ,
      • Writing
      • Group for the DCCT/EDIC Research Group
      Copro­gression of cardiovascular risk factors in type 1 diabetes during 30 years of follow-up in the DCCT/EDIC Study.
      Diabetes Care. 2016; 39: 1621-1630
      ). Participants have undergone repeated measures of common and internal carotid IMT, including measurements at EDIC year 6 (1998–2000), approximately contemporaneous with the blood samples used for our lipoprotein analyses (1997–1999), and 6 years later at EDIC year 12, enabling us to relate lipoprotein characteristics to carotid IMT measurements both cross-sectionally and prospectively. Note that the IMT data show the “means of maximum IMT” for each participant and thus relate to the extent of plaque, if present.
      As in our previous work, some of which included NMR-determined lipoprotein subclasses and certain individual serum apolipoprotein levels (
      • Lyons T.J.
      • Jenkins A.J.
      • Zheng D.
      • Klein R.L.
      • Otvos J.D.
      • Yu Y.
      • Lackland D.T.
      • McGee D.
      • McHenry M.B.
      • Lopes-Virella M.
      • et al.
      Nuclear magnetic resonance-determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with carotid intima-media thickness.
      Diabet. Med. 2006; 23: 955-966
      ,
      • Basu A.
      • Jenkins A.J.
      • Zhang Y.
      • Stoner J.A.
      • Klein R.L.
      • Lopes-Virella M.F.
      • Garvey W.T.
      • Lyons T.J.
      Nuclear magnetic resonance-determined lipoprotein subclasses and carotid intima-media thickness in type 1 diabetes.
      Atherosclerosis. 2016; 244: 93-100
      ,
      • Jenkins A.J.
      • Lyons T.J.
      • Zheng D.
      • Otvos J.D.
      • Lackland D.T.
      • McGee D.
      • Garvey W.T.
      • Klein R.L.
      Serum lipoproteins in the diabetes control and complications trial/epidemiology of diabetes intervention and complications cohort: associations with gender and glycemia.
      Diabetes Care. 2003; 26: 810-818
      ), associations were much more numerous in men than in women. One reason may be that men, compared with women, have more atherogenic lipoprotein profiles and a higher prevalence of vascular complications, including renal disease (which itself worsens the lipoprotein profile). Also, men have increased common and internal carotid IMT compared with women (
      • Dong C.
      • Della-Morte D.
      • Beecham A.
      • Wang L.
      • Cabral D.
      • Blanton S.H.
      • Sacco R.L.
      • Rundek T.
      Genetic variants in LEKR1 and GALNT10 modulate sex-difference in carotid intima-media thickness: a genome-wide interaction study.
      Atherosclerosis. 2015; 240: 462-467
      ,
      • Lerner D.J.
      • Kannel W.B.
      Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population.
      Am. Heart J. 1986; 111: 383-390
      ,
      • Li Z.
      • McNamara J.R.
      • Fruchart J.C.
      • Luc G.
      • Bard J.M.
      • Ordovas J.M.
      • Wilson P.W.
      • Schaefer E.J.
      Effects of gender and menopausal status on plasma lipoprotein subspecies and particle sizes.
      J. Lipid Res. 1996; 37: 1886-1896
      ). Men therefore comprised a majority of our cohort. For these reasons, as in all our previous studies, the sexes were analyzed separately.
      In our cross-sectional analyses in men, the ApoB-containing subclasses, Lp-B, Lp-B:C, and (Lp-B:E + Lp-B:C:E), showed significant positive associations with common and/or internal carotid IMT. We previously reported similar associations with albuminuria, predominantly in men, in the same cohort (
      • Jenkins A.J.
      • Yu J.
      • Alaupovic P.
      • Basu A.
      • Klein R.L.
      • Lopes-Virella M.
      • Baker N.L.
      • Hunt K.J.
      • Lackland D.T.
      • Garvey W.T.
      • et al.
      Apolipoprotein-defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort.
      J. Diabetes Complications. 2013; 27: 447-453
      ), and in the present study we included albuminuria in the adjusted analyses. Relating these subclasses to conventional, density-defined lipoprotein classes, Lp-B is found in the (proatherogenic) LDL class, whereas Lp-B:C and (Lp-B:E + Lp-B:C:E), which showed the strongest associations with IMT, are distributed among the LDL, IDL, and VLDL classes and are highly atherogenic: those containing Apo-E represent atherogenic VLDL remnants (
      • Alaupovic P.
      • Mack W.J.
      • Knight-Gibson C.
      • Hodis H.N.
      The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial.
      Arterioscler. Thromb. Vasc. Biol. 1997; 17: 715-722
      ,
      • Alaupovic P.
      • Heinonen T.
      • Shurzinske L.
      • Black D.M.
      Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels.
      Atherosclerosis. 1997; 133: 123-133
      ). Apo-B-containing ADLS subclasses, especially Lp-B and Lp-B:C, have shown positive correlations with risks of coronary artery disease in patients with hypercholesterolemia (
      • Alaupovic P.
      • Mack W.J.
      • Knight-Gibson C.
      • Hodis H.N.
      The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial.
      Arterioscler. Thromb. Vasc. Biol. 1997; 17: 715-722
      ) and with macroangiopathy in patients with T2D (
      • Gervaise N.
      • Garrigue M.A.
      • Lasfargues G.
      • Lecomte P.
      Triglycerides, apo C3 and Lp B:C3 and cardiovascular risk in type II diabetes.
      Diabetologia. 2000; 43: 703-708
      ). These particles are efficiently taken up by macrophages (
      • Alaupovic P.
      The concept of apolipoprotein-defined lipoprotein families and its clinical significance.
      Curr. Atheroscler. Rep. 2003; 5: 459-467
      ,
      • Alaupovic P.
      • Heinonen T.
      • Shurzinske L.
      • Black D.M.
      Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels.
      Atherosclerosis. 1997; 133: 123-133
      ). Lp-B:C correlates strongly with atherosclerosis progression as reflected by coronary artery calcium scores in patients with rheumatoid arthritis (
      • Knowlton N.
      • Wages J.A.
      • Centola M.B.
      • Giles J.
      • Bathon J.
      • Quiroga C.
      • Alaupovic P.
      Apolipoprotein B-containing lipoprotein subclasses as risk factors for cardiovascular disease in patients with rheumatoid arthritis.
      Arthritis Care Res. (Hoboken). 2012; 64: 993-1000
      ), but no previous studies have reported these associations with carotid IMT in a T1D population. Likewise, the positive associations of (Lp-B:E + Lp-B:C:E) with IMT in men with T1D in our present study is consistent with our prior observation in DCCT-EDIC that the density-defined equivalent of these ADLS, IDL (VLDL remnants), showed the same association when measured by NMR (
      • Lyons T.J.
      • Jenkins A.J.
      • Zheng D.
      • Klein R.L.
      • Otvos J.D.
      • Yu Y.
      • Lackland D.T.
      • McGee D.
      • McHenry M.B.
      • Lopes-Virella M.
      • et al.
      Nuclear magnetic resonance-determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with carotid intima-media thickness.
      Diabet. Med. 2006; 23: 955-966
      ).
      Among serum apolipoproteins in men, Apo-B and measures of Apo-C-III were strongly associated with common and internal carotid IMT in cross-sectional analyses. Elevated Apo-B has been a recognized risk factor for coronary heart disease (
      • Pischon T.
      • Girman C.J.
      • Sacks F.M.
      • Rifai N.
      • Stampfer M.J.
      • Rimm E.B.
      Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men.
      Circulation. 2005; 112: 3375-3383
      ,
      • Walldius G.
      • Jungner I.
      • Holme I.
      • Aastveit A.H.
      • Kolar W.
      • Steiner E.
      High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study.
      Lancet. 2001; 358: 2026-2033
      ) and has been associated with carotid IMT in cohorts with the metabolic syndrome and T2D (
      • Dahlén E.M.
      • Länne T.
      • Engvall J.
      • Lindström T.
      • Grodzinsky E.
      • Nystrom F.H.
      • Ostgren C.J.
      Carotid intima-media thickness and apolipoprotein B/apolipoprotein A-I ratio in middle-aged patients with Type 2 diabetes.
      Diabet. Med. 2009; 26: 384-390
      ,
      • Wallenfeldt K.
      • Bokemark L.
      • Wikstrand J.
      • Hulthe J.
      • Fagerberg B.
      Apolipoprotein B/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men.
      Stroke. 2004; 35: 2248-2252
      ). Total Apo-C-III, Apo-C-III in Apo-B-containing particles (Apo-C-III HP), and an index of the efficiency of triglyceride lipolysis, Apo-C-III ratio (inversely), were all associated with IMT. Apo-C-III can impair plasma lipoprotein metabolism by inhibiting lipoprotein lipase and by blocking the binding of Apo-E to hepatic receptors, thus reducing clearance of Apo-B and triglyceride-rich VLDL particles (
      • Windler E.E.
      • Kovanen P.T.
      • Chao Y.S.
      • Brown M.S.
      • Havel R.J.
      • Goldstein J.L.
      The estradiol-stimulated lipoprotein receptor of rat liver. A binding site that membrane mediates the uptake of rat lipoproteins containing apoproteins B and E.
      J. Biol. Chem. 1980; 255: 10464-10471
      ,
      • Zheng C.
      • Khoo C.
      • Furtado J.
      • Sacks F.M.
      Apolipoprotein C–III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype.
      Circulation. 2010; 121: 1722-1734
      ); it also stimulates monocyte-endothelial adhesion and ensuing inflammation (
      • Kawakami A.
      • Aikawa M.
      • Alcaide P.
      • Luscinskas F.W.
      • Libby P.
      • Sacks F.M.
      Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells.
      Circulation. 2006; 114: 681-687
      ). In a metaanalysis of retrospective and prospective studies, 5 mg/dl increases in total or “non-HDL Apo-C-III” were associated with 33% and 148% increases, respectively, in relative risk for cardiovascular events in high-risk populations (
      • Wyler von Ballmoos M.C.
      • Haring B.
      • Sacks F.M.
      The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis.
      J. Clin. Lipidol. 2015; 9: 498-510
      ). The observed associations of serum Apo-C-III, including its distribution between VLDL and HDL, with IMT are consistent with the association with Lp-B:C discussed above. In the present study, Apo-E and Apo-A-II were also associated with common but not internal carotid IMT in men. Among conventional profiles in men, cross-sectional significance with common carotid IMT was observed only for total cholesterol, and significance with internal carotid IMT was observed for LDL-cholesterol and nonHDL-cholesterol. We therefore conclude that ADLS and detailed apolipoprotein concentrations, particularly those involving Apo-C-III, represent potential biomarkers and mechanistic clues for early atherosclerosis in T1D men.
      Fewer women than men were included in the study, and the extent of their IMT was less. Perhaps for these reasons, few cross-sectional associations between lipoprotein measures and IMT were observed in women, and it is not possible to draw firm conclusions. The paucity of associations is in concert with a smaller study of carotid IMT in 58 women with systemic lupus erythematosus (
      • Kiani A.N.
      • Fang H.
      • Akhter E.
      • Quiroga C.
      • Simpson N.
      • Alaupovic P.
      • Magder L.S.
      • Petri M.
      Apolipoprotein-containing lipoprotein subclasses and subclinical atherosclerosis in systemic lupus erythematosus.
      Arthritis Care Res. 2015; 67: 442-446
      ). A possible association of Apo-C-III with IMT would require confirmation in a larger study, and associations may develop in the future as age and duration of diabetes advance.
      For our prospective analyses, in men, univariate analyses were generally similar to, and consistent with, the cross-sectional findings. The associations with Apo-C-III, while significant for internal carotid IMT, fell just short of statistical significance for common carotid IMT. For women, univariate associations were again scattered and inconclusive. In multivariate analyses, very few significant associations remained in either sex, and those observed were again scattered and had, in general, P values of lesser significance than the cross-sectional analyses. Given these reservations, and even though all observed associations were biologically plausible, conclusions cannot be drawn with confidence; longer studies are needed and are in progress.
      The decreased statistical significance in adjusted vs. univariate prospective analyses could be caused by several confounding factors. We measured lipids and lipoprotein variables at a single time point (EDIC year 6), and, although we adjusted for statin use during the ensuing 6 years, differing durations and intensities of statin therapy and changes in lifestyle and/or other medications could not be taken into account and could have confounded the prospective analyses. Likewise, although we adjusted for prior DCCT randomization group, “metabolic memory” resulting from differing prior glycemic control during DCCT (
      • Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group
      ustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study.
      JAMA. 2003; 290: 2159-2167
      ,
      • Nathan D.M.
      The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 years: overview.
      Diabetes Care. 2014; 37: 9-16
      ) or earlier in EDIC may have had variable long-lasting effects on IMT progression between EDIC years 6 and 12 (
      • Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group
      Effect of intensive diabetes treatment on carotid artery wall thickness in the epidemiology of diabetes interventions and complications.
      Diabetes. 1999; 48: 383-390
      ). Note that the lack of statistically significant associations in the multivariate prospective analyses were not confined to ADLS and apolipoproteins, but extended to conventional lipid profiles as well.
      The multiple statistical tests performed raise concern for an inflated type I error rate beyond the nominal 0.05 α level. Clearly, multiple comparisons were made in the course of the statistical analyses. When we applied the most conservative Bonferroni adjustment (α ≤ 0.001, accounting for the number of comparisons), only serum Apo-B remained significantly associated with common carotid IMT, and only in men and in unadjusted models, a finding consistent with evidence that ApoB is superior to any conventional cholesterol measure (
      • Barter P.J.
      • Ballantyne C.M.
      • Carmena R.
      • Castro Cabezas M.
      • Chapman M.J.
      • Couture P.
      • de Graaf J.
      • Durrington P.N.
      • Faergeman O.
      • Frohlich J.
      • et al.
      Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel.
      J. Intern. Med. 2006; 259: 247-258
      ). However, to explore markers and mechanisms, we consider this stringent level of significance to be excessively conservative: many of the lipoprotein measures are interdependent. For this reason, we presented data in the tables without formal α-level adjustment [as we have done in the past in similar analyses (
      • Lopes-Virella M.F.
      • Carter R.E.
      • Gilbert G.E.
      • Klein R.L.
      • Jaffa M.
      • Jenkins A.J.
      • Lyons T.J.
      • Garvey W.T.
      • Virella G.
      Risk factors related to inflammation and endothelial dysfunction in the DCCT/EDIC cohort and their relationship with nephropathy and macrovascular complications.
      Diabetes Care. 2008; 31: 2006-2012
      ,
      • Hunt K.J.
      • Baker N.L.
      • Cleary P.A.
      • Klein R.
      • Virella G.
      • Lopes-Virella M.F.
      Longitudinal association between endothelial dysfunction, inflammation, and clotting biomarkers with subclinical atherosclerosis in type 1 diabetes: an evaluation of the DCCT/EDIC Cohort.
      Diabetes Care. 2015; 38: 1281-1289
      )]. We also emphasize that all of the associations shown in the tables are biologically plausible.
      We found only scattered and borderline associations between lipoprotein measures and the “change in IMT” between EDIC years 6 and 12. There was little progression of IMT over this time period, likely due, in part, to significant introduction of statin treatment. Clearly, longer follow-up will be needed for a more robust assessment of predictive biomarkers.
      The strengths of our study include the outstanding clinical characterization of DCCT/EDIC participants, the rigorous design of the parent study, the detailed measures of ADLS, apolipoproteins and conventional lipid measurements, and the definition of associations with IMT in both cross-sectional and prospective analyses. The study used samples maintained under stringent conditions since collection, and the assays were conducted in a single laboratory with robust quality control. Important covariate risk factors were taken into account, including statin use (although with the caveat above). The study is the first to define these associations in people with T1D.
      The weaknesses of the study include the necessity, due to assay cost, of including only a subset of the EDIC cohort, the smaller number of women than men, and limited generalizability to other populations. Adjustment for confounding factors in the prospective analyses may have been imperfect. The assays reported, particularly ADLS, require large investments of time, labor, and funds, and standardization across laboratories is challenging: consequently, ADLS analyses are applicable only for research, not for clinical use. Prolonged sample storage could affect ADLS measurements and might result in nondetection of associations. However, in this and other studies using stored sera (
      • Blankenhorn D.H.
      • Alaupovic P.
      • Wickham E.
      • Chin H.P.
      • Azen S.P.
      Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors.
      Circulation. 1990; 81: 470-476
      ,
      • Alaupovic P.
      • Hodis H.N.
      • Knight-Gibson C.
      • Mack W.J.
      • LaBree L.
      • Cashin-Hemphill L.
      • Corder C.N.
      • Kramsch D.M.
      • Blankenhorn D.H.
      Effects of lovastatin on ApoA- and ApoB-containing lipoproteins. Families in a subpopulation of patients participating in the Monitored Atherosclerosis Regression Study (MARS).
      Arterioscler. Thromb. 1994; 14: 1906-1913
      ,
      • Alaupovic P.
      • Fesmire J.D.
      • Hunnighake D.
      • Domanski M.
      • Forman S.
      • Knatterud G.L.
      • Forrester J.
      • Herd J.A.
      • Hoogwerf B.
      • Campeau L.
      • et al.
      The effect of aggressive and moderate lowering of LDL-cholesterol and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial.
      Atherosclerosis. 1999; 146: 369-379
      ,
      • Attman P.O.
      • Samuelsson O.
      • Alaupovic P.
      The effect of decreasing renal function on lipoprotein profiles.
      Nephrol. Dial. Transplant. 2011; 26: 2572-2575
      ), plausible associations were identified, coherent with, and as frequent as those with conventional lipid profiles measured near the time of sample collection. Also, precipitation of apo-B-containing particles using antibodies against other apolipoproteins was similar in extent to that in prior studies, suggesting that particles remained intact. Finally, we recognize the large heterogeneity in lipid and lipoprotein composition: our classification is based on major apolipoproteins only, and other complex variations in composition and posttranslational modifications are known to confer multiple biological effects (
      • Swertfeger D.K.
      • Li H.
      • Rebholz S.
      • Zh X.
      • Shah A.S.
      • Davidson W.S.
      • Lu L.J.
      Mapping atheroprotective functions and related proteins/lipoproteins in size fractionated human plasma.
      Mol. Cell. Proteomics. 2017; 16: 680-693
      ,
      • Godzien J.
      • Ciborowski M.
      • Armitage E.G.
      • Jorge I.
      • Camafeita E.
      • Burillo E.
      • Martin-Ventura J.L.
      • Ruperez F.J.
      • Vazquez J.
      • Barbas C.
      A single in-vial dual extraction strategy for the simultaneous lipidomics and proteomics analysis of HDL and LDL fractions.
      J. Proteome Res. 2016; 15: 1762-1775
      ).

      CONCLUSIONS

      We provide sex-specific and biologically plausible evidence for associations of both ADLS and detailed measures of serum apolipoproteins with common and/or internal carotid IMT, both cross-sectionally and, to a lesser extent, prospectively in people with T1D. Associations were much more frequent in men, and most involved Apo-B-containing particles. Both particle and apolipoprotein data point to an important (adverse) role for Apo-C-III. These associations complement and extend the information yielded by conventional lipid/lipoprotein measures and may help to elucidate new biomarkers and pathogenic mechanisms. Future analyses will relate these detailed measures to “hard” cardiovascular events that are now accruing among DCCT/EDIC participants.

      Acknowledgments

      The authors wish to thank all DCCT/EDIC participating centers and Dr. Barbara Braffett at the EDIC Data Coordinating Center for assistance with the review process and final approval by the DCCT/EDIC Publications and Presentations Committee. Industry contributors that have had no role in the DCCT/EDIC study but have provided free or discounted supplies or equipment to support participants' adherence to the study are as follows: Abbott Diabetes Care (Alameda, CA), Animas (Westchester, PA), Bayer Diabetes Care (North America Headquarters, Tarrytown, NY), Becton Dickinson (Franklin Lakes, NJ), CanAm (Atlanta, GA), Eli Lilly (Indianapolis, IN), Lifescan (Milpitas, CA), Medtronic Diabetes Minneapolis, MI), Omron (Shelton CT), OmniPod® Insulin Management System (Bedford, MA), Roche Diabetes Care (Indianapolis, IN), and Sanofi-Aventis (Bridgewater, NJ).

      REFERENCES

        • Livingstone S.J.
        • Levin D.
        • Looker H.C.
        • Lindsay R.S.
        • Wild S.H.
        • Joss N.
        • Leese G.
        • Leslie P.
        • McCrimmon R.J.
        • Metcalfe W.
        • et al.
        Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008–2010.
        JAMA. 2015; 313: 37-44
        View in Article
        • Lind M.
        • Svensson A.M.
        • Kosiborod M.
        • Gudbjornsdottir S.
        • Pivodic A.
        • Wedel H.
        • Dahlqvist S.
        • Clements M.
        • Rosengren A.
        Glycemic control and excess mortality in type 1 diabetes.
        N. Engl. J. Med. 2014; 371: 1972-1982
        View in Article
        • Jenkins A.J.
        • Lyons T.J.
        • Zheng D.
        • Otvos J.D.
        • Lackland D.T.
        • McGee D.
        • Garvey W.T.
        • Klein R.L.
        Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy.
        Kidney Int. 2003; 64: 817-828
        View in Article
        • Lyons T.J.
        • Jenkins A.J.
        • Zheng D.
        • Klein R.L.
        • Otvos J.D.
        • Yu Y.
        • Lackland D.T.
        • McGee D.
        • McHenry M.B.
        • Lopes-Virella M.
        • et al.
        Nuclear magnetic resonance-determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with carotid intima-media thickness.
        Diabet. Med. 2006; 23: 955-966
        View in Article
        • Kearney P.M.
        • Blackwell L.
        • Collins R.
        • Keech A.
        • Simes J.
        • Peto R.
        • Armitage J.
        • Baigent C.
        Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.
        Lancet. 2008; 371: 117-125
        View in Article
        • Basu A.
        • Jenkins A.J.
        • Zhang Y.
        • Stoner J.A.
        • Klein R.L.
        • Lopes-Virella M.F.
        • Garvey W.T.
        • Lyons T.J.
        Nuclear magnetic resonance-determined lipoprotein subclasses and carotid intima-media thickness in type 1 diabetes.
        Atherosclerosis. 2016; 244: 93-100
        View in Article
        • Garvey W.T.
        • Kwon S.
        • Zheng D.
        • Shaughnessy S.
        • Wallace P.
        • Hutto A.
        • Pugh K.
        • Jenkins A.J.
        • Klein R.L.
        • Liao Y.
        Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance.
        Diabetes. 2003; 52: 453-462
        View in Article
        • Alaupovic P.
        Significance of apolipoproteins for structure, function, and classification of plasma lipoproteins.
        Methods Enzymol. 1996; 263: 32-60
        View in Article
        • Alaupovic P.
        The concept of apolipoprotein-defined lipoprotein families and its clinical significance.
        Curr. Atheroscler. Rep. 2003; 5: 459-467
        View in Article
        • Puchois P.
        • Kandoussi A.
        • Fievet P.
        • Fourrier J.L.
        • Bertrand M.
        • Koren E.
        • Fruchart J.C.
        Apolipoprotein A-I containing lipoproteins in coronary artery disease.
        Atherosclerosis. 1987; 68: 35-40
        View in Article
        • Blankenhorn D.H.
        • Alaupovic P.
        • Wickham E.
        • Chin H.P.
        • Azen S.P.
        Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors.
        Circulation. 1990; 81: 470-476
        View in Article
        • Alaupovic P.
        • Hodis H.N.
        • Knight-Gibson C.
        • Mack W.J.
        • LaBree L.
        • Cashin-Hemphill L.
        • Corder C.N.
        • Kramsch D.M.
        • Blankenhorn D.H.
        Effects of lovastatin on ApoA- and ApoB-containing lipoproteins. Families in a subpopulation of patients participating in the Monitored Atherosclerosis Regression Study (MARS).
        Arterioscler. Thromb. 1994; 14: 1906-1913
        View in Article
        • Ooi E.M.
        • Barrett P.H.
        • Chan D.C.
        • Watts G.F.
        Apolipoprotein C–III: understanding an emerging cardiovascular risk factor.
        Clin. Sci. (Lond.). 2008; 114: 611-624
        View in Article
        • Ginsberg H.N.
        • Le N.A.
        • Goldberg I.J.
        • Gibson J.C.
        • Rubinstein A.
        • Wang-Iverson P.
        • Norum R.
        • Brown W.V.
        Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.
        J. Clin. Invest. 1986; 78: 1287-1295
        View in Article
        • Windler E.E.
        • Kovanen P.T.
        • Chao Y.S.
        • Brown M.S.
        • Havel R.J.
        • Goldstein J.L.
        The estradiol-stimulated lipoprotein receptor of rat liver. A binding site that membrane mediates the uptake of rat lipoproteins containing apoproteins B and E.
        J. Biol. Chem. 1980; 255: 10464-10471
        View in Article
        • Zheng C.
        • Khoo C.
        • Furtado J.
        • Sacks F.M.
        Apolipoprotein C–III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype.
        Circulation. 2010; 121: 1722-1734
        View in Article
        • Blackett P.R.
        • Blevins K.S.
        • Quintana E.
        • Stoddart M.
        • Wang W.
        • Alaupovic P.
        • Lee E.T.
        ApoC-III bound to apoB-containing lipoproteins increase with insulin resistance in Cherokee Indian youth.
        Metabolism. 2005; 54: 180-187
        View in Article
        • Kowal R.C.
        • Herz J.
        • Weisgraber K.H.
        • Mahley R.W.
        • Brown M.S.
        • Goldstein J.L.
        Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein.
        J. Biol. Chem. 1990; 265: 10771-10779
        View in Article
        • The Diabetes Control and Complications Trial Research Group
        • Nathan D.M.
        • Genuth S.
        • Lachin J.
        • Cleary P.
        • Crofford O.
        • Davis M.
        • Rand L.
        • Siebert C.
        The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
        N. Engl. J. Med. 1993; 329: 977-986
        View in Article
        • The Diabetes Control and Complications Trial Research Group
        • Nathan D.M.
        • Genuth S.
        • Lachin J.
        • Cleary P.
        • Crofford O.
        • Davis M.
        • Rand L.
        • Siebert C.
        Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort.
        Diabetes Care. 1999; 22: 99-111
        View in Article
        • Jenkins A.J.
        • Yu J.
        • Alaupovic P.
        • Basu A.
        • Klein R.L.
        • Lopes-Virella M.
        • Baker N.L.
        • Hunt K.J.
        • Lackland D.T.
        • Garvey W.T.
        • et al.
        Apolipoprotein-defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort.
        J. Diabetes Complications. 2013; 27: 447-453
        View in Article
        • Nathan D.M.
        • Lachin J.
        • Cleary P.
        • Orchard T.
        • Brillon D.J.
        • Backlund J.Y.
        • O'Leary D.H.
        • Genuth S.
        Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus.
        N. Engl. J. Med. 2003; 348: 2294-2303
        View in Article
        • Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group
        Effect of intensive diabetes treatment on carotid artery wall thickness in the epidemiology of diabetes interventions and complications.
        Diabetes. 1999; 48: 383-390
        View in Article
        • Polak J.F.
        • Backlund J.Y.
        • Cleary P.A.
        • Harrington A.P.
        • O'Leary D.H.
        • Lachin J.M.
        • Nathan D.M.
        Progression of carotid artery intima-media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Dia­betes Interventions and Complications (DCCT/EDIC) study.
        Diabetes. 2011; 60: 607-613
        View in Article
        • Attman P.O.
        • Alaupovic P.
        • Gustafson A.
        Serum apolipoprotein profile of patients with chronic renal failure.
        Kidney Int. 1987; 32: 368-375
        View in Article
        • Hilpert K.F.
        • West S.G.
        • Kris-Etherton P.M.
        • Hecker K.D.
        • Simpson N.M.
        • Alaupovic P.
        Postprandial effect of n-3 polyunsaturated fatty acids on apolipoprotein B-containing lipoproteins and vascular reactivity in type 2 diabetes.
        Am. J. Clin. Nutr. 2007; 85: 369-376
        View in Article
        • März W.
        • Trommlitz M.
        • Gross W.
        Differential turbidimetric assay for subpopulations of lipoproteins containing apolipoprotein A-I.
        J. Clin. Chem. Clin. Biochem. 1988; 26: 573-578
        View in Article
        • Jenkins A.J.
        • Lyons T.J.
        • Zheng D.
        • Otvos J.D.
        • Lackland D.T.
        • McGee D.
        • Garvey W.T.
        • Klein R.L.
        Serum lipoproteins in the diabetes control and complications trial/epidemiology of diabetes intervention and complications cohort: associations with gender and glycemia.
        Diabetes Care. 2003; 26: 810-818
        View in Article
        • The DCCT Research Group
        Feasibility of centralized measurements of glycated hemoglobin in the Diabetes Control and Complications Trial: a multicenter study.
        Clin. Chem. 1987; 33: 2267-2271
        View in Article
        • Nathan D.M.
        • McGee P.
        • Steffes M.W.
        • Lachin J.M.
        Relationship of glycated albumin to blood glucose and HbA1c values and to retinopathy, nephropathy, and cardiovascular outcomes in the DCCT/EDIC study.
        Diabetes. 2014; 63: 282-290
        View in Article
        • Lopes-Virella M.F.
        • Baker N.L.
        • Hunt K.J.
        • Lyons T.J.
        • Jenkins A.J.
        • Virella G.
        High concentrations of AGE-LDL and oxidized LDL in circulating immune complexes are associated with progression of retinopathy in type 1 diabetes.
        Diabetes Care. 2012; 35: 1333-1340
        View in Article
        • Writing
        • Group for the DCCT/EDIC Research Group
        Copro­gression of cardiovascular risk factors in type 1 diabetes during 30 years of follow-up in the DCCT/EDIC Study.
        Diabetes Care. 2016; 39: 1621-1630
        View in Article
        • Dong C.
        • Della-Morte D.
        • Beecham A.
        • Wang L.
        • Cabral D.
        • Blanton S.H.
        • Sacco R.L.
        • Rundek T.
        Genetic variants in LEKR1 and GALNT10 modulate sex-difference in carotid intima-media thickness: a genome-wide interaction study.
        Atherosclerosis. 2015; 240: 462-467
        View in Article
        • Lerner D.J.
        • Kannel W.B.
        Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population.
        Am. Heart J. 1986; 111: 383-390
        View in Article
        • Li Z.
        • McNamara J.R.
        • Fruchart J.C.
        • Luc G.
        • Bard J.M.
        • Ordovas J.M.
        • Wilson P.W.
        • Schaefer E.J.
        Effects of gender and menopausal status on plasma lipoprotein subspecies and particle sizes.
        J. Lipid Res. 1996; 37: 1886-1896
        View in Article
        • Alaupovic P.
        • Mack W.J.
        • Knight-Gibson C.
        • Hodis H.N.
        The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial.
        Arterioscler. Thromb. Vasc. Biol. 1997; 17: 715-722
        View in Article
        • Gervaise N.
        • Garrigue M.A.
        • Lasfargues G.
        • Lecomte P.
        Triglycerides, apo C3 and Lp B:C3 and cardiovascular risk in type II diabetes.
        Diabetologia. 2000; 43: 703-708
        View in Article
        • Alaupovic P.
        • Heinonen T.
        • Shurzinske L.
        • Black D.M.
        Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels.
        Atherosclerosis. 1997; 133: 123-133
        View in Article
        • Knowlton N.
        • Wages J.A.
        • Centola M.B.
        • Giles J.
        • Bathon J.
        • Quiroga C.
        • Alaupovic P.
        Apolipoprotein B-containing lipoprotein subclasses as risk factors for cardiovascular disease in patients with rheumatoid arthritis.
        Arthritis Care Res. (Hoboken). 2012; 64: 993-1000
        View in Article
        • Pischon T.
        • Girman C.J.
        • Sacks F.M.
        • Rifai N.
        • Stampfer M.J.
        • Rimm E.B.
        Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men.
        Circulation. 2005; 112: 3375-3383
        View in Article
        • Walldius G.
        • Jungner I.
        • Holme I.
        • Aastveit A.H.
        • Kolar W.
        • Steiner E.
        High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study.
        Lancet. 2001; 358: 2026-2033
        View in Article
        • Dahlén E.M.
        • Länne T.
        • Engvall J.
        • Lindström T.
        • Grodzinsky E.
        • Nystrom F.H.
        • Ostgren C.J.
        Carotid intima-media thickness and apolipoprotein B/apolipoprotein A-I ratio in middle-aged patients with Type 2 diabetes.
        Diabet. Med. 2009; 26: 384-390
        View in Article
        • Wallenfeldt K.
        • Bokemark L.
        • Wikstrand J.
        • Hulthe J.
        • Fagerberg B.
        Apolipoprotein B/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men.
        Stroke. 2004; 35: 2248-2252
        View in Article
        • Kawakami A.
        • Aikawa M.
        • Alcaide P.
        • Luscinskas F.W.
        • Libby P.
        • Sacks F.M.
        Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells.
        Circulation. 2006; 114: 681-687
        View in Article
        • Wyler von Ballmoos M.C.
        • Haring B.
        • Sacks F.M.
        The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis.
        J. Clin. Lipidol. 2015; 9: 498-510
        View in Article
        • Kiani A.N.
        • Fang H.
        • Akhter E.
        • Quiroga C.
        • Simpson N.
        • Alaupovic P.
        • Magder L.S.
        • Petri M.
        Apolipoprotein-containing lipoprotein subclasses and subclinical atherosclerosis in systemic lupus erythematosus.
        Arthritis Care Res. 2015; 67: 442-446
        View in Article
        • Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group
        ustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study.
        JAMA. 2003; 290: 2159-2167
        View in Article
        • Nathan D.M.
        The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 years: overview.
        Diabetes Care. 2014; 37: 9-16
        View in Article
        • Barter P.J.
        • Ballantyne C.M.
        • Carmena R.
        • Castro Cabezas M.
        • Chapman M.J.
        • Couture P.
        • de Graaf J.
        • Durrington P.N.
        • Faergeman O.
        • Frohlich J.
        • et al.
        Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel.
        J. Intern. Med. 2006; 259: 247-258
        View in Article
        • Lopes-Virella M.F.
        • Carter R.E.
        • Gilbert G.E.
        • Klein R.L.
        • Jaffa M.
        • Jenkins A.J.
        • Lyons T.J.
        • Garvey W.T.
        • Virella G.
        Risk factors related to inflammation and endothelial dysfunction in the DCCT/EDIC cohort and their relationship with nephropathy and macrovascular complications.
        Diabetes Care. 2008; 31: 2006-2012
        View in Article
        • Hunt K.J.
        • Baker N.L.
        • Cleary P.A.
        • Klein R.
        • Virella G.
        • Lopes-Virella M.F.
        Longitudinal association between endothelial dysfunction, inflammation, and clotting biomarkers with subclinical atherosclerosis in type 1 diabetes: an evaluation of the DCCT/EDIC Cohort.
        Diabetes Care. 2015; 38: 1281-1289
        View in Article
        • Alaupovic P.
        • Fesmire J.D.
        • Hunnighake D.
        • Domanski M.
        • Forman S.
        • Knatterud G.L.
        • Forrester J.
        • Herd J.A.
        • Hoogwerf B.
        • Campeau L.
        • et al.
        The effect of aggressive and moderate lowering of LDL-cholesterol and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial.
        Atherosclerosis. 1999; 146: 369-379
        View in Article
        • Attman P.O.
        • Samuelsson O.
        • Alaupovic P.
        The effect of decreasing renal function on lipoprotein profiles.
        Nephrol. Dial. Transplant. 2011; 26: 2572-2575
        View in Article
        • Swertfeger D.K.
        • Li H.
        • Rebholz S.
        • Zh X.
        • Shah A.S.
        • Davidson W.S.
        • Lu L.J.
        Mapping atheroprotective functions and related proteins/lipoproteins in size fractionated human plasma.
        Mol. Cell. Proteomics. 2017; 16: 680-693
        View in Article
        • Godzien J.
        • Ciborowski M.
        • Armitage E.G.
        • Jorge I.
        • Camafeita E.
        • Burillo E.
        • Martin-Ventura J.L.
        • Ruperez F.J.
        • Vazquez J.
        • Barbas C.
        A single in-vial dual extraction strategy for the simultaneous lipidomics and proteomics analysis of HDL and LDL fractions.
        J. Proteome Res. 2016; 15: 1762-1775
        View in Article

      Article info

      Publication history

      Published online: March 25, 2018
      Accepted: February 15, 2018
      Received: August 23, 2017

      Footnotes

      This project was funded by National Institutes of Health Grant R01DK080043 andAmerican Diabetes Association Grant 7-12-CT-46. DCCT/EDIC has been supported by Division of Diabetes Endocrinology and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Diseases U01 cooperative agreement grants (1982–1993 and 2011–2016) and contracts (1982–2011); and through support by the National Eye Institute, the National Institute of Neurological Disorders and Stroke, theGenetic Clinical Research Centers Program (1993–2007), and the Clinical Translational Science Center Program (2006–present; Bethesda, MD). The content is solely the responsibility of the authors and does not necessarily represent the official views of theNational Institutes of Health. The authors declare no competing interests.

      The online version of this article (available at http://www.jlr.org) contains a supplement.

      Abbreviations:

      ADLS
      apolipoprotein-defined lipoprotein subclass
      AER
      albumin excretion rate
      Apo-C-III ratio
      ratio of Apo-C-III HS to Apo-C-III HP
      HbA1C
      hemoglobin A1C
      HP
      heparin precipitate
      HS
      heparin-soluble
      IMT
      intima-media thickness
      Lp-A-I
      lipoprotein whose only apolipoprotein is Apo-A1
      Lp-B
      lipoprotein whose only apolipoprotein is Apo-B
      MUSC
      Medical University of South Carolina
      TG
      triacylglycerol

      Identification

      DOI: https://doi.org/10.1194/jlr.P080143

      Copyright

      User license

      Creative Commons Attribution (CC BY 4.0) |
      How you can reuse Information Icon
      Creative Commons Attribution (CC BY 4.0)

      Permitted

      • Read, print & download
      • Redistribute or republish the final article
      • Text & data mine
      • Translate the article
      • Reuse portions or extracts from the article in other works
      • Sell or re-use for commercial purposes

      Elsevier's open access license policy

      ScienceDirect

      Access this article on ScienceDirect

      ASBMB  ASBMB  ASBMB  ASBMB

      ISSN 0022-2275
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2022 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX